Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope

International Journal of Cancer

Volumn 71, Issue 3, 1997, Pages 491-496

  Zajac, Paul ^a   Oertli, Daniel ^a   Spagnoli, Giulio C ^a   Noppen, Christoph ^a   Schaefer, Christoph ^a   Heberer, Michael ^a   Marti, Walter R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE;

ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; BASE SEQUENCE; BLOOD DONORS; CELL LINE; COS CELLS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REFERENCE VALUES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0031006759     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970502)71:3<491::AID-IJC30>3.0.CO;2-G     Document Type: Article

References (26)

1. ANDERSON, K., CRESSWELL, P., GAMMON, M., HERMES, J., WILLIAMSON, A. and ZWEERINK, H., Endogenously synthesized peptide with an endoplasmaticreticulum signal sequence sensitizes antigen processing mutant cells to class-I-restricted cell-mediated lysis. J. exp. Med., 174, 489-492 (1991).
2. BACIK, I., Cox, J.H., ANDERSON, R., YEWDELL, J.W. and BENNINK, J.R., TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmicreticulum insertion sequences located at the amino- but not carboxylterminus of the peptide. J. Immunol, 152, 381-387 (1994).
3. BARKER, A.B.H., MARLAND, G., DE BOER, A., HUIJBENS, R.J.F., DANEN, E.H.J., ADEMA, G.J. and FIGDOR, C.G., Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55, 5330-5334 (1995).
4. CHEN, Y.T., STOCKERT, E., JUNGBLUTH, A., TSANG, S., COPLAN, K.A., SCANLAN, M.J. and OLD, L.J., Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. nat. Acad. Sci. (Wash.), 93, 5915-5919 (1996).
5. COONEY, E.L., COLLIER, A.C., GREENBERG, P.D., COOMBS, R.T., ZARLING, J., ARDITTI, D.E., HUFFMAN, M.C., HU, S.L. and CUREY, L., Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337, 567-572 (1991).
6. DALGLEISH, A., The case of therapeutic vaccines. Melanoma Res., 6, 5-10 (1996).
7. FlLGUElRA, L., ZUBER, M., JURETIC, A., LUSCHER, U., CAETANO, V., HARDER. F., GAROTTA, G., HEBERER, M. and SPAGNOLI, G.C., Differential effects of interleukin-2 and CD3 triggering on cytokine-gene transcription and secretion in cultured tumor-infiltrating lymphocytes. Cell. Immunol., 150, 205-218 (1993).
8. IRVINE, K.R., MCCABE, B.J., ROSENBERG, S.A. and RESTIFO, N.P., Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol., 154, 4651-4657 (1995).
9. JAEGER, E., BERNHARD, H., ROMERO, P., RINGHOFFER, M., ARAND, M., KARBACH, J., ILSEMANN, C., HAGEDORN, M. and KNUTH, A., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer, 66, 162-169 (1996).
10. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.P., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor-infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
11. LANE, J.M., RUBEN, F.L., NEFF, J.M. and MILLAR, J.D., Complications of smallpox vaccination. 1968. National surveillance in the United States. New Engl. J. Med., 281, 1201-1208 (1969).
12. (27,35). J. exp. Med., 184, 647-657 (1996).
13. MARCHAND, M. and 20 OTHERS, Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, (letter), 883-885 (1995).
14. MARTI, W.R., OERTLI, D., MEKO, J.B., NORTON, J.A. and TSUNG, K., Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and co-stimulatory molecules. J. Immunol. Methods (1997). (In press).
15. MCANENY, D., RYAN, C.A., BEAZLEY, R.M. and KAUFMAN, H.L., Results of a phase-I trial of a recombinant vaccinia virus that expresses CEA in patients with advanced colorectal cancer. Ann. surg. Oncol., 3, 495-500 (1996).
16. Moss, B., Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. nat. Acad. Sci. (Wash.), 93, 11341-11348 (1996).
17. - spleocytes in vitro. J. gen. Virol. 77, 3121-3125 (1996).
18. PAOLETTI, E., Applications of poxvirus vectors to vaccination: an update. Proc. nat. Acad. Sci. (Wash.), 93, 11349-11353 (1996).
19. RESTIFO, N.P., BACIK, I., IRVINE, K.R., YEWDELL, J.W., MCCABE, B.J., ANDERSON, R.W., EISENLOHR, L.C., ROSENBERG, S.A. and BENNINK, J.R., Antigen processing in vivo and the elicitation of primary CTL responses, J. Immunol., 154, 4414-4422 (1995).
20. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.F., MARINCOLA, F.M., SALGALLER, M.L., YANNELLI, J.R., APPHLLA, E. and ROSENBERG, S.A., Induction of tumor-reactive CTL from peripheral-blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154, 2257-2265 (1995).
21. RIVOLTINI, L., LOFTUS, D.J., BARRACCHINI, K., ARIENTI, F., MAZZOCCHI, A., BIDDISON, W.E., SALGALLER, M.L., APPELLA, E., PARMIANI, G. and MARINCOLA, F.M., Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 sub-types. Implications for peptide-based immunotherapy. J. Immunol., 156, 3882-3891 (1996).
22. SPAGNOLI, G.C., SCHAEFER, C., WILLIMANN, T.E., KOCHER, T., AMOROSO, A., JURETIC, A., ZUBER, M., LUSCHER, U., HARDER, F. and HEBERER, M., Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer, 64, 309-315 (1995).
23. Toso, J.F., OEI, C., OSHIDARI, F., TARTAGLIA, J., PAOLETTI, E., LYERLY, H.K., TALIB, S. and WEINHOLD, K.J., MAGE-1-specific precursor cytotoxic T lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res., 56, 16-20 (1996).
24. TSUNG, K., YIM, J.H., MARTI, W.R., BULLER, M.L. and NORTON, J.A., Gene expression and cytopathic effect of chemically inactivated vaccinia virus. J. Virol., 70, 165-171 (1996).
25. VAN ELSAS, A., VAN DER BURG, S.H., VAN DER MINNE, C.E., BORGHI, M., MOURER, J.S., MELIEF, C.J.M. and SCHRIER, P.I., Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably MHL-A*0201-bindina peptides from the Melan-A/MART-1 self-antigen. Europ. J. Immunol., 26, 1683-1689 (1996).
26. ZHAI, Y., YANG, J.C., KAWAKAMI, Y., SPIESS, P., WADSWORTH, S.C., CARDOZA, L.M., COUTURE, L.A., SMITH, A.E. and ROSENBERG, S.A., Antigen-specific tumor vaccines, Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156, 700-710 (1996).